The growing global drive for risk reduction means that biopharmaceutical manufacturers and their supply partners are faced with several challenges. They must continue to guarantee the thermal integrity of their products – often maintaining tighter temperatures ranges – while still working to constantly improve the speed and price to market of their products in order to ensure a maximum level of product efficacy and, ultimately, patient reach.
The use of phase change materials seems to be the way forward in making this process cost-effective while improving efficacy at the same time. Cold Chain Technologies Jamie Chasteen and Topa Thermal’s Richard Harrop discuss this topic in Pharma cold chain logistics in the fall issue of Pharmaceutical Manufacturing Packaging Sourcer (PMPS).
Read More >>>